Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDE9A | O76083 | 1/20 | 0.51 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19952892 | 0.80 | FASN (0.66) | FASNKDM4ECSF1RMEN1KMT2A | |
| SCHEMBL29611969 | 0.80 | FASN (0.66) | FASNKDM4ECSF1RMEN1KMT2A | |
| SCHEMBL10647703 | 0.79 | FASN (0.65) | FASNKDM4ECSF1RMEN1KMT2A | |
| SCHEMBL5330425 | 0.79 | KDM4E (0.70) | FASNKDM4EMAPTCSF1RPADI4 | |
| SCHEMBL15648185 | 0.79 | KDM4E (0.70) | FASNKDM4EMAPTMEN1KMT2A | |
| SCHEMBL14449851 | 0.79 | KDM4E (0.70) | FASNKDM4EMAPTCSF1R | |
| SCHEMBL13936059 | 0.78 | FASN (1.00) | FASNKDM4EMAPT | |
| SCHEMBL4458789 | 0.78 | FASN (0.74) | FASNKDM4EMAPTCSF1R | |
| SCHEMBL4452981 | 0.78 | FASN (1.00) | FASNKDM4EMAPT | |
| SCHEMBL4465756 | 0.78 | KDM4E (0.68) | FASNKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1981341-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | Merck and Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | FASN 1/4885KDM4E 1768/4885MAPT 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.